Association of cyclooxygenase 2 polymorphic genotypes with prostate cancer in Taiwan

Anticancer Research

Volumn 31, Issue 1, 2011, Pages 221-225

  Wu, Hsi Chin ^a   Chang, Chao Hsiang ^a   Ke, Hung Lung ^b,c   Chang, Wen Shin ^a   Cheng, Hui Ni ^a   Lin, Hui Hui ^c   Wu, Chi Yu ^d   Tsai, Chia Wen ^a,e   Tsai, Ru Yin ^a   Lo, Woei Chung ^a   Bau, Da Tian ^a,e  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d Chang Hua Hospital   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Carcinogenesis; Cox 2; Polymorphism; Prostate cancer

Indexed keywords

CYCLOOXYGENASE 2;

ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN;

ALLELES; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; DNA, NEOPLASM; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; TAIWAN;

EID: 79851506233     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Department of Health, Executive Yuan, Taiwan. Summary of Statistics on Causes of Death in Taiwan, 2008.
2. DeWitt DL: Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta 1083: 121-134, 1991.
3. Kujubu DA, Reddy ST, Fletcher BS and Herschman HR: Expression of the protein product of the prostaglandin synthase-2/TIS10 gene in mitogen-stimulated Swiss 3T3 cells. J Biol Chem 268: 5425-5430, 1993. (Pubitemid 23090858)
4. Kawata R, Reddy ST, Wolner B and Herschman HR: Prostaglandin synthase 1 and prostaglandin synthase 2 both participate in activation-induced prostaglandin D2 production in mast cells. J Immunol 155: 818-825, 1995.
5. Reddy ST and Herschman HR: Ligand-induced prostaglandin synthesis requires expression of the TIS10/PGS-2 prostaglandin synthase gene in murine fibroblasts and macrophages. J Biol Chem 269: 15473-15480, 1994. (Pubitemid 24202129)
6. Fujimura T, Ohta T, Oyama K, Miyashita T and Miwa K: Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol 12: 1336-1345, 2006.
7. Marshall SF, Bernstein L, Anton-Culver H, Deapen D, Horn-Ross PL, Mohrenweiser H, Peel D, Pinder R, Purdie DM, Reynolds P, Stram D, West D, Wright WE, Ziogas A and Ross RK: Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 97: 805-812, 2005. (Pubitemid 40909123)
8. van Rees BP and Ristimaki A: Cyclooxygenase-2 in carcinogenesis of the gastrointestinal tract. Scand J Gastroenterol 56: 897-903, 2001.
9. Wang W, Bergh A and Damber JE: Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 11: 3250-3256, 2005. (Pubitemid 40627872)
10. Cok SJ and Morrison AR: The 3′-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 276: 23179-23185, 2001.
11. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE and Laurent GJ: Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22: 1631-1636, 2002.
12. Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G and Witte JS: COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer 97: 557-561, 2007. (Pubitemid 47258446)
13. Panguluri RC, Long LO, Chen W, Wang S, Coulibaly A, Ukoli F, Jackson A, Weinrich S, Ahaghotu C, Isaacs W and Kittles RA: COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 25: 961-966, 2004. (Pubitemid 38886082)
14. Shahedi K, Lindstrom S, Zheng SL, Wiklund F, Adolfsson J, Sun J, Augustsson-Balter K, Chang BL, Adami HO, Liu W, Gronberg H and Xu J: Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer 119: 668-672, 2006. (Pubitemid 43955722)
15. Fernandez P, de Beer PM, van der Merwe L and Heyns CF: COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men. Carcinogenesis 29: 2347-2350, 2008.
16. Bau DT, Tseng HC, Wang CH, Chiu CF, Hua CH, Wu CN, Liang SY, Wang CL, Tsai CW and Tsai MH: Oral cancer and genetic polymorphism of DNA double-strand break gene Ku70 in Taiwan. Oral Oncol 44: 1047-1051, 2008.
17. Bau DT, Wu HC, Chiu CF, Lin CC, Hsu CM, Wang CL, Wang RF and Tsai FJ: Association of XPD polymorphisms with prostate cancer in Taiwanese patients. Anticancer Res 27: 2893-2896, 2007.
18. Chang CH, Chiu CF, Liang SY, Wu HC, Chang CL, Tsai CW, Wang HC, Lee HZ and Bau DT: Significant association of Ku80 single nucleotide polymorphisms with bladder cancer susceptibility in Taiwan. Anticancer Res 29: 1275-1279, 2009.
19. Liu CJ, Hsia TC, Wang RF, Tsai CW, Chu CC, Hang LW, Wang CH, Lee HZ, Tsai RY and Bau DT: Interaction of cyclooxygenase 2 genotype and smoking habit in Taiwanese lung cancer patients. Anticancer Res 30: 1195-1199, 2010.
20. Tseng HC, Tsai MH, Chiu CF, Wang CH, Chang NW, Huang CY, Tsai CW, Liang SY, Wang CL and Bau DT: Association of XRCC4 codon 247 polymorphism with oral cancer susceptibility in Taiwan. Anticancer Res 28: 1687-1691, 2008.
21. Wark PA, Van der Kuil W, Ploemacher J, Van Muijen GN, Mulder CJ, Weijenberg MP, Kok FJ and Kampman E: Diet, lifestyle and risk of K-ras mutation-positive and -negative colorectal adenomas. Int J Cancer 119: 398-405, 2006.